AssetMark Inc
RARE icon

AssetMark Inc’s Ultragenyx Pharmaceutical RARE Stock Holding History

AssetMark Inc’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$34.6K Buy
2,304
+857
+59% +$20.6K ﹤0.01% 2028
2026
Q2 		$48.3K Hold
1,447
– – ﹤0.01% 1845
2026
Q1 		$30.3K Buy
1,447
+371
+34% +$8.35K ﹤0.01% 1918
2025
Q4 		$24.7K Sell
1,076
-8
-0.7% -$263 ﹤0.01% 1934
2025
Q3 		$32.6K Buy
1,084
+1,024
+1,707% +$30.7K ﹤0.01% 1785
2025
Q2 		$2.18K Buy
60
+54
+900% +$1.95K ﹤0.01% 2403
2025
Q1 		$217 Hold
6
– – ﹤0.01% 2524
2024
Q4 		$252 Buy
+6
New +$298 ﹤0.01% 2459
2022
Q4 		– Sell
-18
Closed -$1K – 1646
2022
Q3 		$1K Sell
18
-4,522
-100% -$232K ﹤0.01% 1473
2022
Q2 		$271K Buy
4,540
+102
+2% +$6.28K ﹤0.01% 705
2022
Q1 		$322K Buy
4,438
+2,354
+113% +$164K ﹤0.01% 681
2021
Q4 		$175K Buy
2,084
+2,005
+2,538% +$163K ﹤0.01% 725
2021
Q3 		$7K Buy
+79
New +$7.14K ﹤0.01% 1098
2020
Q1 		– Sell
-31
Closed -$1K – 1506
2019
Q4 		$1K Hold
31
– – ﹤0.01% 1332
2019
Q3 		$1K Buy
31
+18
+138% +$978 ﹤0.01% 1259
2019
Q2 		$1K Hold
13
– – ﹤0.01% 1263
2019
Q1 		$1K Sell
13
-1
-7% -$57 ﹤0.01% 1270
2018
Q4 		$1K Buy
+14
New +$765 ﹤0.01% 1345
2018
Q1 		– Sell
-12
Closed -$1K – 1865
2017
Q4 		$1K Buy
+12
New +$588 ﹤0.01% 1682
2016
Q1 		– Sell
-5
Closed -$1K – 1363
2015
Q4 		$1K Buy
+5
New +$500 ﹤0.01% 1251

Other funds holding RARE

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jefferies Financial Group
Jefferies Financial Group New York $13.5B AUM 36.68% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

AssetMark Inc's RARE Position: Q3 2026 in Review

AssetMark Inc increased its Ultragenyx Pharmaceutical (RARE) stake by 59% in Q3 2026, buying an estimated $20.6K and bringing the position to 2,304 shares worth $34.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

AssetMark Inc first reported a position in RARE in Q4 2015 and has held it in 20 quarters since. The position peaked at $322K in Q1 2022. 84 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • AssetMark Inc held 2,304 shares of Ultragenyx Pharmaceutical worth $34.6K as of Q3 2026.
  • AssetMark Inc bought 857 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $20.6K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of AssetMark Inc's portfolio in Q3 2026, its #2028 holding.
  • AssetMark Inc first reported a position in Ultragenyx Pharmaceutical in Q4 2015 and has held it in 20 quarters since.
  • AssetMark Inc's Ultragenyx Pharmaceutical position peaked at $322K in Q1 2022.
  • 84 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on AssetMark Inc's 13F filing for Q3 2026, filed 21 Oct 2026.